Maravai Lifesciences Holdings (MRVI) Total Liabilities (2020 - 2026)

Maravai Lifesciences Holdings' Total Liabilities history runs 7 years deep, the most recent figure standing at $344.1 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 19.87% year-over-year to $344.1 million in Q1 2026; TTM through Mar 2026 was $344.1 million, a 19.87% decrease from a year earlier, with the FY2025 full-year figure at $397.9 million, down 7.7% from the prior year.
• Total Liabilities declined to $344.1 million in Q1 2026 per MRVI's latest filing, from $397.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.4 billion in Q1 2023 and bottomed at $344.1 million in Q1 2026.
• The 5-year median for Total Liabilities is $671.3 million (2024), against an average of $875.2 million.
• Across the five-year window, Total Liabilities advanced 21.62% in 2022 and tumbled 52.84% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $1.4 billion in 2022, then tumbled by 49.34% to $697.6 million in 2023, then tumbled by 38.21% to $431.0 million in 2024, then retreated by 7.7% to $397.9 million in 2025, then decreased by 13.51% to $344.1 million in 2026.
• Per Business Quant, the three latest MRVI Total Liabilities figures stand at $344.1 million (Q1 2026), $397.9 million (Q4 2025), and $417.3 million (Q3 2025).